

Special Issue

Bacterial Capsule Conjugate Vaccines

Message from the Guest Editor

Emerging infectious diseases, particularly COVID-19, have invigorated the field of vaccinology. The dramatic success in terms of the speed of development and the efficacy of the new class of mRNA vaccines have raised expectations for vaccines to control future outbreaks. mRNA is just one of many platforms that will be used for vaccine development. DNA vaccines made from eukaryotic expression plasmids have shown great promise for decades. Viral vectors including those made from adenoviruses, VSV, and Vaccinia viruses have developed into mature vaccine platforms. Even bacteriophages and bacteria spores have been used to express foreign antigens to the immune system. Nanoparticle vaccines made from self-assembling proteins such as the HBV capsid protein and ferritin have made their way into clinical trials. More conventional protein subunit vaccines are also becoming easier to design and produce, taking advantage of sequencing data, recombinant DNA technologies, and synthetic methods.

Guest Editor

Dr. Donald J. Chabot

Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA

Deadline for manuscript submissions

closed (30 December 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/79219

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).